Severe sepsis is a life-threatening condition, which affects over 18 million people each year.

“Unfortunately, most know someone who had developed a severe infection. It could have been something as catastrophic as a ruptured appendix, or something more common as pneumonia, maybe a bad urinary tract infection or even influenza — where the infection got out of hand and sent that person to the intensive care unit on life support, with failing critical organs like the hearts, lungs, and kidneys,” says Dr. Phillip Chan, MD, PhD, the Chief Executive Officer of the company.

“Despite the best medical care here in the United States, one in every three patients die of this disease, and in fact, more people die of severe sepsis in the United States than from either heart attacks or strokes or any single form of cancer. It remains a major unmet medical need.”

While massive resources have been invested in developing and evaluating potential therapies, MedaSorb is conducting human trials in Europe and has already announced preliminary positive proof of concept in humans, using CytoSorb™ to treat severe sepsis patients.

“Our major goal (for 2010) is the successful completion of our trial, which will hopefully lead to CE Mark approval,” Chan said.

Dr. Michael Stampar, D.O., Senior Medical Advisor to SinoFresh HealthCare Products, stated, “We are very encouraged by this initial study report and will continue to develop data to support our belief that SinoFresh Nasal Spray, a broad-based antiseptic solution, is an important component in protecting the health of patients that are exposed to the H1N1 (’swine flu’) virus.”

The study, which was conducted by SRS International Corp. of Falls Church, VA, was conducted over 14 days and was designed to evaluate the severity of infection from H1N1 (”swine flu”) virus in the Cotton Rat animal model, a well accepted model for studying human nasal and respiratory tract infection by viruses and other microbial pathogens. In this study, the test animals were inoculated with H1N1 and then received SinoFresh Nasal Spray in the nose three times daily for 14 days.

The study evaluated the product’s likelihood of efficacy in both prevention and treatment. One group of animals was treated with SinoFresh Nasal Spray prior to inoculation with H1N1 and a second group was treated starting 15 minutes after inoculation with H1N1 while the remaining “control group” received no treatment during the overall 14-day study period.

The Company has now also initiated a study to evaluate the product’s ability to reduce or eliminate viral shedding which is the main method of transmission of the H1N1 flu virus. The active phase of the additional study has been completed and is in the laboratory for evaluation. Results are expected in the next few weeks.

About SinoFresh(TM) HealthCare, Inc.

SinoFresh(TM) HealthCare, Inc. is a developer and marketer of therapies to treat inflammatory and infectious diseases of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms suspected of causing pathogenesis of the mouth nose and throat. The Company holds certain patents and patent applications on its innovative pharmaceutical technology and relies upon a panel of medical experts and management team experienced in the bio-pharmaceutical industry.

The Company’s product, SinoFresh(TM) Nasal & Sinus Care, is the only over-the-counter antiseptic nasal spray that kills bacteria and fungi and viral pathogens in the throat and nasal passages. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that affects many Americans annually. More information is available at www.sinofresh.com.

*SinoFresh(TM) is a trademark of SinoFresh HealthCare, Inc.

For further information company can be contacted at 888-460-4774, or on the web at www.sinofreshproducts.com, or by email at customerservice@sinofreshproducts.com.

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company’s filings with the Securities and Exchange commission, including risks summarized in the company’s annual Report of form 10-KSB for its fiscal year ended December 31, 2006 (file No.49764). The Company’s actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments.

Contact:
SinoFresh
888-460-4774
www.sinofreshproducts.com
customerservice@sinofreshproducts.com

About InfuSystem Holdings, Inc.

InfuSystem is the leading supplier of infusion services to oncologists and other outpatient treatment settings. The Company provides pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. The Company’s unique suite of services appeals to practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes.

CONTACT:
Asher Dewhurst
Bob East
Westwicke Partners
(443) 213-0500

Gross profit from continuing operations decreased $58,000, or 4%, in the quarter to $1.5 million, primarily driven by an 11% decrease in revenue compared to prior year, attributable to a 17% decrease in blood products revenue. This was the result of increased competition caused by an unprecedented excess supply of blood products in the United States due to the recent downturn in the economy. Gross profit margin from continuing operations in the quarter was 17%, compared to 16% in the third quarter of 2008.

Commenting on the results, John Doumitt, the Company’s Chief Executive Officer, stated, “While this was a challenging revenue quarter for the Company, we are pleased to have maintained profitability and are gratified that we were able to recently add new customers who recognize the important value we provide.”


Contact:
HemaCare Corporation
Robert S. Chilton
Executive Vice President and Chief Financial Officer
877-310-0717
www.hemacare.com

Previously in June of 2009, Bio-Path Holdings, Inc. issued a press release in which drug development operations and the status of commencing a Phase I clinical trial in the Company`s lead drug candidate were discussed. In that update, the Company indicated that the next major milestones were successful manufacturing of the clinical drug batch to be used in the Phase I trial, and submission of all drug manufacturing and testing data to the U.S. Food and Drug Administration (FDA). The Company confirms today that its suppliers have successfully manufactured the clinical drug batch, and that all release testing required for this drug has been completed. As a result, Bio-Path Holdings, Inc. in October submitted the necessary drug batch manufacturing and testing data to the FDA. Assuming FDA reviewers have no additional requests for information, the Company expects within 30 days that the Investigational New Drug (IND) application for its lead drug candidate will be released. Bio-Path Holdings, Inc. would then be able to commence its Phase I clinical trial.

About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. is developing leading-edge, patented, liposomal drug delivery systems developed at The University of Texas M. D. Anderson Cancer Center, with two clinical cancer drug candidates ready for the clinic, and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path`s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded (siRNA) and single stranded (antisense) nucleic acid compounds, with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.

Bio-Path Holdings, Inc. will also be developing liposome tumor targeting
technology, representing next-generation enhancements to the Company`s core
liposome delivery technology.

Bio-Path Holdings, Inc.
Internal Public Relations:
Douglas P. Morris, VP Corporate Development
801-580-2326